Weak sales, CMO orders contribute to SK bioscience losses
Published: 28 Jul. 2023, 16:47
![A medical staff holds a vial of SKYCovione vaccine, developed and manufactured by SK bioscience, at a public health center in Incheon [YONHAP]](https://koreajoongangdaily.joins.com/data/photo/2023/07/28/767707b3-d508-49f8-b952-858ce437a7c1.jpg)
A medical staff holds a vial of SKYCovione vaccine, developed and manufactured by SK bioscience, at a public health center in Incheon [YONHAP]
It reported 35.3 billion won ($28 million) in operating loss for the April-June period from an operating profit of 61.2 billion won a year earlier.
It still beat the market consensus of 20.8 billion won of losses compiled by FnGuide.
Revenues fell 80.9 percent to 26.5 billion won, beating the consensus of 21.6 billion won.
Net also turned red to 16 billion won in net losses, swinging from a profit of 46.1 billion won a year earlier.
BY SARAH CHEA [[email protected]]
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)